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g.2013.1Abstract Background: Medicinal plants have been a major source of therapeutic agents from
ancient times to cure diseases. The evaluation of rich heritage of traditional medicine is essential.
The bark of Terminalia arjuna is rich in polyphenols (60–70%) including ﬂavonoids and tannins.
Aim: The aim of the present investigation is to highlight the anticarcinogenic and antimutagenic
potential of extracts of T. arjuna.
Subject and methods: In this experiment we have used human lymphocyte culture and bone mar-
row cells of albino mice as assay system. The parameters studied included chromosomal aberrations
(CA), sister chromatid exchanges (SCEs) and cell growth kinetics (RI) both in the presence and in
the absence of exogenous metabolic activation system for in vitro experiment, whereas total aber-
rant cells and the total frequencies of aberrations were taken for in vivo study.
Results: The role of T. arjuna extracts in reducing metaphase aberrations due to aﬂatoxin B1 is
quite signiﬁcant, the reduction varying from 23.49%, 42.47%, and 59.65% down to 12.32%,ation, SCE, sister chromatid
aﬂatoxin B1, TA, Terminalia
l metabolic activation system
9335753122.
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Table 1 In vivo effect of Terminalia
(AFB1 x/kg.bw) at 16, 24 and 32 h
Treatment TA/kg.bw Cell
chro
DDH2O 00 00
AFB1 00 11
TA TA5 00
AFB1 + TA(16 h) TA1 08
TA2 07
TA3 04
TA4 03
TA5 02
TA1 07
AFB1 + TA(24 h) TA2 05
TA3 04
TA4 03
TA5 02
TA1 07
AFB1 + TA(32 h) TA2 06
TA3 04
TA4 01
TA5 00
Note: TA1–TA5; concentrations of Ter
distilled water. Calculations were mad
tration of Terminalia arjuna extracts.
62 M.S. Ahmad et al.28.00%, and 36.88% respectively at the highest dose (TA4) for the three different durations viz., 24,
48 and 72 h. Similarly the number of sister chromatid exchanges got reduced from a higher level of
15.00 ± 1.40 per cell to 7.70 ± 0.50 per cell with S9 mix at 48 h of treatment. The replication index
was enhanced from 1.33 to 1.55 in vitro. Similar trends were noticed in the in vivo experiments i.e.,
effective reductions in clastogeny ranging from 15.22% to 54.82% from the mutagen treated posi-
tive control and the total frequencies in aberrant cells got reduced from 429 due to AFB1 to 141 due
to 5th concentration of Terminalia extracts at 32 h of exposure.
Conclusion: The ameliorating potential of Terminalia extracts was dose and time dependant.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
The evaluation of the rich heritage of traditional medicine is an
important task for pharmacologist. In this regard the Termina-
lia arjuna is one such plant, which is distributed throughout the
Indian Peninsula and is abundantly found in Sub-Himalayan
tract. In the Indian system of medicine, the bark of the plant
is used for curing ulcers, leucorrhoea, diabetes, tumor, asthma
and inﬂammation etc. [1].
It was earlier observed that tannins andﬂavonoids are respon-
sible for their anticancer properties [2]. Theremay be some chem-
ical agents present in plants that may act as anticarcinogen or
antimutagen by blocking or trapping ultimate carcinogen elec-
trophile in a nucleophilic chemical reaction to form innocuous
products. It was shown that the bark of T. arjuna is rich in poly-
phenols (60–70%) including ﬂavonoids, tannins and triterpe-
noids [3]. These constituents are mainly responsible for
anticancer activity. According to Sumitra et al. [4] the constitu-
ents of T. arjuna such as arjunolic acid and ascorbic acid arrest
a decrease in antioxidant system, alpha tocopherol reduced glu-
tathione as well as lipid peroxide and protect the heart fromdam-
age caused due to myocardial necrosis which is induced by
isoproterenol. In a study by Devi et al. [5] the gastro-protectivearjuna extracts on the frequency
durations.
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minalia arjuna extracts, Aﬂatoxin B
e excluding the gap type of aberraproperties ofT. arjuna inDiclofenac sodium induced gastric ulcer
in rats due to its scavenging action of free radical and cyto-pro-
tective nature. The T. arjuna preparation at 50 mg/kg of body
weight of dose, signiﬁcantly decreases the higher level of the anti-
oxidants produced by carbon tetrachloride induced oxidative
stress and increases the reduced glutathione content. It also de-
creases the lipid peroxidation and its products [6]. A triterpenoid
saponin, arjunin isolated from the arjuna plant ameliorates ar-
senic induced cyto-toxicity in isolated murine hepatocytes via
normalizing the altered enzymatic and non-enzymatic levels [7].
In another study, the anti-inﬂammatory and immunomodula-
tory activities of the bark in mice and rats were also reported
[8]. The aim of the present investigation is to highlight the anti-
carcinogenic and antimutagenic potential of T. arjuna extracts
in vitro and in vivo.2. Materials and methods
2.1. Aﬂatoxins B1
Aﬂatoxins are produced by Aspergillus ﬂavus and A. parasiti-
cus at any time during growth and post harvest storage of aof cells with chromosomal aberrations induced by Aﬂatoxin B1
atic aberrations Aberrant cell no. (%) Reduction (%)
Fragments Exchanges
27 00 31 (3.1)
98 10 197 (19.7)
28 00 34 (3.4
86 07 167 (16.7) 15.22
80 06 150 (15.0) 23.85*
68 03 124 (12.4) 37.05*
60 03 115 (11.5) 41.62*
57 01 99 (9.9) 49.75*
81 06 157 (15.7) 20.30
76 05 140 (14.0) 28.93*
60 02 114 (11.4) 42.13*
54 02 105 (10.5) 46.70*
51 01 92 (9.2) 53.30*
83 05 155 (15.5) 21.32
78 04 145 (14.5) 26.40*
72 02 134 (13.4) 31.98*
60 01 110 (11.0) 44.16*
47 01 89 (8.9) 54.82*
1 5 lg/ml /kg body weight at at 16, 24 and 32 h of treatment. DH2O;
tion and *signiﬁcant at <0.05 probability. TA/kg.bw is the concen-
Figure 1 Showing in vivo anticarcinogenic effect of Terminalia
arjuna at 16, 24, and 31 h of treatment durations against Aﬂatoxin
B1 genotoxicity in Albino mice bone marrow cell (signiﬁcant at
P< 0.05 level).
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hanced under poor food harvesting and storage practices
[9,10] that lead to aﬂatoxin B1 exposure to human. The major
concern with respect to human health derives from the high
potency of aﬂatoxins to produce cancer in laboratory animals
and correlates with the evidence that AFB1 is a liver carcino-
gen in human populations [11–13].Table 2 In vivo effect of Terminalia arjuna extracts on the frequency
(AFB1 x/kg.bw) at 16, 24 and 32 h durations.
Treatment TA/kg.bw Cell with aberration
0 1 2
DH2O 00 969 27 04
AFB1 00 803 103 32
TA TA5 966 28 06
AFB1 + TA(16 h) TA1 833 105 25
TA2 850 97 19
TA3 876 83 17
TA4 885 83 13
TA5 901 75 09
TA1 843 89 22
TA2 860 87 17
AFB1 + TA(24 h) TA3 886 75 14
TA4 895 78 10
TA5 908 68 9
TA1 845 90 23
TA2 855 92 19
AFB1 + TA(32 h) TA3 866 91 17
TA4 890 79 12
TA5 911 64 09
Note: TA1–TA5; concentrations of Terminalia arjuna extracts; AFB1, Aﬂ
DH2O; distilled water. Calculations were made excluding the gap type o
concentration of Terminalia arjuna extracts. The animals were sacriﬁced a
was analyzed for each point.2.2. Terminalia arjuna
The name Terminalia is derived from latin ‘Teminalis’ due to
terminal crowding of the leaves in many species of the genus
Terminalia [14]. It belongs to the family Combretaceae. It is
a large deciduous tree with buttressed roots, and reaches up
to 60–70 feet. Stem is covered with white–gray bark which
changes its color to pink according to season and age of the
bark, and ﬂakes off in large ﬂat pieces from the trunk [1].
2.3. Extract preparation
The sun dried bark of T. arjuna was brought to the laboratory
and powdered and extracted in water (1:8, after passing
through 80 mesh size) by boiling (4 h). The extracts were sub-
sequently ﬁltered through muslin cloth and the ﬁltrate was
spray dried. For preparation of water solution of T. arjuna ex-
tracts, dried powder (500 mg), was dissolved in distilled water
and then centrifuged (500g, 15 min). The supernatants were
transferred to micro-centrifuge tubes and stored (at 20 C).
The amount of total soluble solids in supernatant was mea-
sured using gravimetric analysis which served as the basis to
formulate T. arjuna concentrations.
We have selected four optimum doses of T. arjuna suspen-
sion viz., 75, 100, 150 and 200 lg/ml for lymphocyte culture
in vitro and ﬁve doses viz., 50, 100, 150, 250 and 350 mg/kg
body weight for in vivo experiments.
2.4. In vivo study
Albino mice 8–10 weeks old (25–35 gm in weight) were ex-
posed to mutagen and different concentrations of Terminaliaof cells with chromosomal aberrations induced by Aﬂatoxin B1
Total number of aberration
3 4 5 6–9
00 00 00 00 35
25 16 12 09 429
00 00 00 00 40
19 12 09 07 357
15 08 06 05 279*
12 06 05 03 239*
09 06 03 01 183
07 05 03 00 149*
18 13 08 07 329
16 09 06 05 272*
12 06 04 03 205*
09 04 03 01 163*
07 05 03 00 142*
17 11 08 06 316
15 08 06 05 274*
12 06 05 03 233
09 06 03 01 177
08 05 03 00 141*
atoxin B1 5 lg/ml /kg body weight at16, 24 and 32 h of treatment.
f aberration and *signiﬁcant at <0.05 probability. TA/kg.bw is the
t 16, 24 and 32 h after AFB1 treatment of 1000 cells from 10 animals
Table 3 In vitro analysis of chromosomal aberration after treatment with Aﬂatoxin B1 (AFB1) along with Terminalia arjuna extracts,
in the absence of -S9 mix.
Treatments Durations (h) Metaphase scored Percent aberration metaphase Types of aberration (%) Aberration/cell ± SE
Including gap Excluding gap Chromatid Chromosome Total
AFB1 24 200 26.12 23.00 17.15 6.34 23.49 0.23 ± 0.03
48 200 44.00 40.17 29.47 13.00 42.47 0.42 ± 0.05
72 200 47.27 42.00 38.12 21.53 59.65 0.60 ± 0.08
AFB1 + TA1 24 200 22.22 19.51 14.00 5.87 19.87 0.20 ± 0.04
48 200 40.00 36.41 26.53 11.00 37.53 0.38 ± 0.06
72 200 43.18 38.21 35.18 18.50 53.68 0.54 ± 0.09
AFB1 + TA2 24 200 21.32 18.32 12.00 5.47 17.47 0.17 ± 0.03
48 200 38.73 34.00 21.13 10.13 31.26 0.31 ± 0.06
72 200 41.00 36.67 34.39 15.25 49.64 0.50 ± 0.08
AFB1 + TA3 24 200 20.00 16.00 10.00 4.00 14.00 0.14 ± 0.04
48 200 37.65 32.38 19.68 8.27 27.95 0.28 ± 0.05
72 200 39.00 34.77 27.98 12.75 40.73 0.41 ± 0.09
AFB1 + TA4 24 200 19.12 15.12 08.22 4.10 12.32 0.12 ± 0.03
48 200 37.00 31.89 20.00 08.00 28.00 0.28 ± 0.06
72 200 38.19 33.61 25.88 11.00 36.88 0.37 ± 0.06
Control
Normal 72 200 2.78 2.33 1.98 0.77 2.75 0.03 ± 0.01
DMSO+ TA2 72 200 3.88 1.56 2.58 1.00 3.58 0.04 ± 0.01
Note: TA1–TA4; concentrations of Terminalia arjuna extracts, AFB1 x/kg.bw; Aﬂatoxin B1 5 lg/ml/culture, gap type of aberration is not
included, SE; Standard error, DMSO; dimethyl sulphoxide. Calculations were signiﬁcant at <0.05 probability level.
Figure 3 In vitro anticlastogenic effect of Terminalia arjuna in
the presence of S9 mixture at 24, 48 and 72 h of treatment
durations (signiﬁcant at P< 0.05 level).
Figure 2 Comparative in vitro anticlastogenic effect of Termi-
nalia arjuna in the absence of S9 mixture at 24, 48 and 72 h of
treatment durations (signiﬁcant at P< 0.05 level).
64 M.S. Ahmad et al.extract preparation by appropriate routes (intra peritoneal i.e.,
I.P injection) and were sacriﬁced at sequential intervals of 16,
24, and 32 h of stipulated treatment time. Animals were treated
with each test substance as mentioned above. Further pro-
cesses of slide preparation, the cells and chromosomal aberra-
tion analyses are adopted from an earlier published work [15].
The reduction factors due to test chemical treatments were
calculated using the formula published earlier [16]. The work
was carried out following the guideline of institutional ethics
committee and in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) for hu-
mans and animals.2.5. In vitro lymphocyte culture method
The chromosomal changes (numerical and structural) were uti-
lized for the investigation of the genotoxic as well as antigen-
otoxic potentiality of test chemicals. The parameters studied
included chromosomal aberrations (CA), sister chromatid ex-
changes (SCEs) and cell growth kinetics (RI) both in the pres-
ence and in the absence of exogenous metabolic activation
system. The in vitro culture methods, preparation of S9
(microsomal fraction), media preparation and analyses of
Table 4 In vitro analysis of sister chromatid exchanges (SCE) after treatment with Aﬂatoxin B1 along with Terminalia arjuna extract,
in the absence as well as presence of S9 mix.
Treatment Duration (h) Metabolic activation Metaphase scanned Total SCE Range SCE/cell ± SE
Aﬂatoxin B1 48 S9 50 610 2–12 12.20 ± 1.00
+S9 750 15.00 ± 1.40
AFB1 + TA1 48 S9 50 555 2 – 10 11.10 ± 1.00
+S9 640 12.80 ± 1.00
AFB1 + TA2 48 S9 50 490 1–08 9.80 ± 0.74
+S9 505 10.10 ± 1.00
AFB1 + TA3 48 S9 50 370 0 – 7 7.40 ± 0.50
+S9 455 9.10 ± 0.70
AFB1 + TA4 48 S9 50 318 0 – 6 6.36 ± 0.44
+S9 385 7.70 ± 0.50
Normal 48 +S9 50 75 0 – 6 1.50 ± 0.20
DMSO 48 +S9 50 66 0 – 7 1.32 ± 0.20
DMSO+ TA2 48 +S9 50 72 0–6 1.44 ± 0.20
Note: TA1–TA4; concentrations of Terminalia arjuna, AFB1 x/kg.bw; Aﬂatoxin B1 5 lg/ml/culture, SE; Standard error, DMSO; dimethyl
sulphoxide. Calculations were signiﬁcant at <0.05 probability level.
Terminalia arjuna, a herbal remedy against environmental carcinogenicity 65chromosomal aberrations, sister chromatid exchanges, cell cy-
cle kinetics and statistical analysis were followed as per the
methodology published earlier [15,16].
3. Results
3.1. In vivo effect of Terminalia arjuna extracts
After 16 h of treatments the percentages of aberrant cells ob-
tained were 16.7%, 15.0%, 12.4%, 11.5% and 9.9% respec-
tively at the ﬁve increasing concentrations of T. arjuna
extracts as compared to 19.7% of aberrant cells induced by
Aﬂatoxin B1 alone. Fragment types of aberrations were most
prominent followed by breaks and gaps. In terms of percent-Figure 4 Antigenotoxic effect of Terminalia arjuna on sister
chromatid exchanges in the absence as well as in the presence of
metabolic activation system. Total 50 metaphase plates were
scored at 48 h of treatment durations (signiﬁcant at P< 0.05
level).age reduction in the frequencies of aberrant cells, the values
were 15.22%, 23.85%, 37.055%, 41.62% and 49.75% due to
ﬁve different concentrations of T. arjuna extracts given with
AFB1 as compared with positive control respectively (Table 1
Fig. 1).
The gross effects on the total frequencies of aberrations per
thousand cells were 357, 279, 239, 183 and 149 due to ﬁve dif-
ferent doses of Terminalia extracts along with AFB1, against
429 aberrations of Aﬂatoxin B1 when given alone. The normal
control value was 40 for only Terminalia extract treatment
without AFB1 added. Most of the cells have one or two aber-
rations per cell. When the treatment durations were increased
to 24 h, the effects followed similar trends, but with increasing
values. The observed values were 15.7%, 14.0%, 11.4%,
10.5% and 9.2% respectively at ﬁve concentrations of Termi-
nalia extracts given with AFB1 against only 19.7% aberrant
cells for Aﬂatoxin B1 alone, whereas normal value was 3.4
for Terminalia extracts as shown in Fig. 1.
The effect of Terminalia extracts in reducing the frequency
of aberrations per cell and the total number of aberrations
were statistically signiﬁcant at <0.05 level. The total aberra-
tions per thousand cells were 329, 272, 205, 163 and 142 for
Terminalia extracts given with AFB1 against 429 with Aﬂa-
toxin B1 alone. Further, the animals were exposed to 32 h;
the increase in aberrant cells observed was 15.5%, 14.5%,
13.4%, 11.0% and 8.9% for ﬁve increasing doses of Terminalia
extracts against the normal control value which was 3.1%. The
effects on reduction in aberrant cells were 21.32%, 26.40%,
31.98%, 44.16% and 54.82% respectively, which were statisti-
cally signiﬁcant. It shows almost a dose-dependent relationship
as shown in Tables 1 and 2 and Fig. 1.
3.2. In vitro effect of Terminalia arjuna extracts
The role of T. arjuna extracts in reducing metaphase aberra-
tions due to Aﬂatoxin B1 is quite signiﬁcant, varying from un-
treated positive control values (23.49%, 42.47%, and 59.65%)
to treated ones (12.32%, 28.00%, and 36.88%) at the highest
dose (E4) for the three different durations viz., 24, 48 and
72 h. There was no change in basal clastogeny of the cell
(2.75% and 3.58%) by T. arjuna extracts. The effects showed
Table 5 In vitro analysis of cell cycle kinetics after treatment with Aﬂatoxin B1 along with Terminalia arjuna extract, in the presence of
S9 mix.
Treatment Cell scored Metabolic activation Percent aberration metaphase Replication index 2\3 chi square test
M1 M2 M3
Aﬂatoxin B1 200 S9 64 33 03 1.37
+S9 69 29 02 1.33
AFB1 + TA1 200 S9 60 35 05 1.45 Signiﬁcant
+S9 65 32 03 1.38
AFB1 + TA2 200 S9 56 37 07 1.51 Signiﬁcant
+S9 62 33 05 1.41
AFB1 + TA3 200 S9 50 41 09 1.58 Signiﬁcant
+S9 59 35 06 1.47
AFB1 + TA4 200 S9 45 45 10 1.65 Signiﬁcant
+S9 53 39 08 1.55
Normal 200 S9 39 47 14 1.75
DMSO 200 +S9 39 46 15 1.76
DMSO+ TA2 200 +S9 38 47 15 1.77
Note: 2 · 3 Chi square (v2) test was conducted, TA1–TA4; concentrations of Terminalia arjuna, AFB1 x/kg.bw; Aﬂatoxin B1 5 lg/ml/culture,
DMSO; dimethyl sulphoxide. Calculations were made at <0.05 probability level.
66 M.S. Ahmad et al.a linear dose–response relationship. The effective maximum
reductions in the clastogeny were 47.55%, 34.07% and
38.17% percent at three different durations respectively as
shown in Table 3 Fig. 2. Similarly in the presence of S9 meta-
bolic activation system, the same values were reduced to
49.93%, 33.67% and 35.34% (Fig. 3).
The effect on sister chromatid exchange counts was simi-
larly reduced; however the experiments were conducted only
for 48 h for all treatments including control. The 50 metapha-
ses were scored for each treatment along with S9 treatment as
shown in Table 4 Fig. 4. The aﬂatoxin B1 produced 12.20 per
cell and 15.0 per cell SCE in the absence as well as in the pres-
ence of S9 mix respectively. These values were reduced to 06.36
SCE per cell and 07.70 SCE per cell due to the highest concen-
tration of Terminalia extracts as compared with aﬂatoxin B1
values.
The replication index calculated showed a signiﬁcant eleva-
tion of R.I in comparison to aﬂatoxin B1treatment. Here, the
dose–effect relationship was linear as shown in Table 5.
4. Discussion
Due to global environmental pollution and modern life style,
there has been an increase in the rate of mutations leading to
cancer. The ways to neutralize the effect of such mutagenic
and carcinogenic agents is to identify the substances that can
antagonize their effects. Plants are the promising sources of
antimutagens found in them as secondary metabolites [17].
In earlier studies, we have shown the antimutagenic and anti-
carcinogenic potential of vitamins, carotenoids and extracts of
Caesalpinia bonducella and Agaricus bisporus [15,16,18,19].
These antimutagenic agents may help in strengthening the cell
defense mechanism against environmental carcinogens. It has
been suggested earlier that halving the rate of mutations would
delay the onset of most cancers and might be adequate in the
lifetime of many individuals [20]. T. arjuna is a well known
medicinal plant, particularly its bark is extensively used in
ayurvedic medicines. Keeping in mind the medicinal impor-
tance of T. arjuna, the present study aimed at observing the
anticarcinogenic and antimutagenic potential of this medicinalplant with the potential to combat a number of mutagens and
carcinogens.
Tannins and ﬂavones in the leaves, barks and stems of T.
arjuna were reported to be responsible mainly for anticancer
activity [21]. Antimutagenic assay of ethyl ether extracts of arj-
una bark carried out by using the ‘comet’ assay and micronu-
clei test revealed that extracts are effective in reducing the
DNA damage induced by 4NQO [22]. Increased levels of plas-
ma and the liver glycolytic enzymes and decreased level of glu-
cose- 6-phosphatase were reverted to normal by depleting the
energy metabolism and inhibiting the cancer growth account-
ing for its anticancer potential [23]. Luteolin, a ﬂavone isolated
from the butanol fraction of T. arjuna was found to be effec-
tive in inhibiting a series of solid tumors (Renal A-549, ovary
SK-OV-3, Brain SF-295, etc.). It also acted as an antitumor
promoter and had antimutagenic properties [24]. It was also
reported the efﬁcacy of T. arjuna in inhibiting the proliferation
of the human hepatoma cell lines (HepG2) as well as a potent
inhibitor of CYP isoform that prevents the conversion of
cyclophosphamide or aﬂatoxin B1 to its genotoxic metabolite
[25,26]. Its antimutagenic effect may be due to the direct pro-
tection of DNA from electrophilic mutagens or their metabo-
lites or by formation of adducts that may result in the
prevention of genotoxic damage [27]. The effect of bark extract
of T. arjuna was studied on the alteration of adriamycin
(ADR)-induced micronuclei formation in cultured human
peripheral blood lymphocytes. These results demonstrate that
extract of T. arjuna protects DNA against ADR-induced dam-
age [28] that was parallel to our ﬁnding in vitro using replica-
tion index parameter.
5. Conclusion
The role of T. arjuna extracts in reducing metaphase aberra-
tions due to aﬂatoxin B1 is quite signiﬁcant, the reduction
varying from 23.49%, 42.47%, and 59.65% down to
12.32%, 28.00%, and 36.88% respectively at the highest dose
(E4) for the three different durations viz., 24, 48 and 72 h. Sim-
ilarly the number of sister chromatid exchanges got reduced
from higher level of 15.00 ± 1.40 per cell to 7.70 ± 0.50 per
Terminalia arjuna, a herbal remedy against environmental carcinogenicity 67cell with S9 mix at 48 h of treatment. The replication index was
enhanced from 1.33 to 1.55 in vitro. Similar trends were no-
ticed in the in vivo experiments i.e., effective reductions in clas-
togeny ranging from 15.22% to 54.82% from the mutagen
treated positive control and the total frequencies in aberrant
cells got reduced from 429 due to AFB1 to 141 due to 5th con-
centration of Terminalia extracts at 32 h of exposure. The ame-
liorating potential of Terminalia extracts was dose and time
dependant.
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